Semaglutide, a weight-loss drug developed by Novo Nordisk, is currently in short supply due to high demand, leading some people to seek out "generic" or compounded versions of the drug instead, Sophie Putka reports for MedPage Today. But obesity specialists warn against using compounded semaglutide since its quality and safety cannot be guaranteed.| www.advisory.com
Novo Nordisk continues to face supply shortages for its Wegovy (semaglutide) pens, which are FDA approved for weight management.| Drug Discovery and Development
Ozempic (semaglutide) is a non-insulin medication that helps patients with type 2 diabetes lose weight. Buy Ozempic Online from Canada & SAVE.| Buy Canadian Insulin
Experience effective weight loss, Calibrate clinicians prescribe GLP-1 medications like Ozempic, Wegovy, Zepbound alongside a holisitic program. Learn more.| www.joincalibrate.com
The Treat and Reduce Obesity Act (H.R. 4231/S. 1973) Congress must support and advance bipartisan legislation to ensure Medicare beneficiaries can access safe, effective, and life-saving treatments for obesity. The Treat and Reduce Obesity Act (TROA) aims to address the obesity epidemic and improve access to tools for the prevention and treatment of obesity forRead Article| Obesity Action Coalition
Chad Nauseam Home| chadnauseam.com